TMPRSS2 and COVID-19: Inhibitors such as camostat have shown success in lowering SARS-CoV-2 infection in lung cells, indicating that targeting TMPRSS2 could be an attractive option for addressing COVID-19; additionally, when paired alongside other protease inhibitors such as furin inhibitors, these TMPRSS2 inhibitors have shown a combined effect that significantly diminishes viral entry and infection rates [95, 123].